Wang Shouman相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

SHR-A1811, a novel HER2-targeting antibody-drug conjugate, in advanced solid tumors (HORIZON-X): a global phase 1 trial

SHR-A1811，一种新型靶向 HER2 的抗体药物偶联物，在晚期实体瘤中的应用（HORIZON-X）：一项全球 1 期试验

期刊:Signal Transduction and Targeted Therapy

影响因子:52.7

doi:10.1038/s41392-026-02612-9

Yao, Herui; Yan, Min; Tong, Zhongsheng; Wu, Xinhong; Yin, Yongmei; Ryu, Min-Hee; Park, John J; Jiang, Shusuan; Kim, Jee Hyun; Wang, Shouman; Zhong, Yahua; Voskoboynik, Mark; Zhang, Jian; Kaubisch, Andreas; Liu, Caigang; Chen, Yu; Im, Seock-Ah; Wu, Lingying; Liu, Yingbin; Ganju, Vinod; Barve, Minal; Li, Hui; Yao, Guangyu; Yang, Mudan; Bao, Lequn; Zhao, Yiming; Zhao, Jianli; Zhao, Kaijing; Shen, Yu; Rong, Shangyi; Zhu, Xiaoyu; Song, Erwei

发表日期：2026

文献求助收藏

Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study

曲妥珠单抗和吡咯替尼联合达匹西利新辅助治疗HR阴性/HER2阳性乳腺癌的疗效和安全性：一项探索性、开放标签的II期研究

期刊:International Journal of Surgery

影响因子:10.1

doi:10.1097/JS9.0000000000003328

Xiao, Zhi; Chen, Feiyu; Liao, Liqiu; Luo, Shayang; Liu, Xuan; Liu, Xiangyan; Xu, Tao; Hu, Yu; Luo, Na; Wang, Wenlong; Cao, Jing; Wang, Kuansong; Zhou, Haiyan; Ding, Nianhua; Li, Yan; Huang, Juan; Wang, Shouman

发表日期：2026

文献求助收藏

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial

卡瑞利珠单抗联合化疗作为早期或局部晚期三阴性乳腺癌患者新辅助治疗的疗效比较：CamRelief随机临床试验

期刊:Journal of the American Medical Association

影响因子:55

doi:10.1001/jama.2024.23560

Chen, Li; Li, Hui; Zhang, Hao; Yang, Huawei; Qian, Jun; Li, Zhihua; Ren, Yu; Wang, Shu; Fu, Peifen; Yang, Hongjian; Liu, Yunjiang; Sun, Jing; Nie, Jianyun; Lei, Ruiwen; Yao, Yongzhong; Zhang, Anqin; Wang, Shouman; Ma, Xiaopeng; Ouyang, Zhong; Yang, Hongwei; Wu, Song-Yang; Cao, Shuo-Wen; Wang, Kun; Jiang, Aimei; Ouyang, Quchang; Pang, Da; Wei, Limin; Zha, Xiaoming; Shen, Yu; Qu, Xiangwen; Wu, Fei; Zhu, Xiaoyu; Wang, Zhonghua; Fan, Lei; Shao, Zhi-Ming

发表日期：2025

文献求助收藏

Single-cell transcriptome analysis reveals the malignant characteristics of tumour cells and the immunosuppressive landscape in HER2-positive inflammatory breast cancer.

单细胞转录组分析揭示了 HER2 阳性炎性乳腺癌中肿瘤细胞的恶性特征和免疫抑制图谱

期刊:Journal of Experimental & Clinical Cancer Research

影响因子:12.8

doi:10.1186/s13046-025-03454-z

Huang Juan, Zhu Yongwei, Zeng Wenjing, Zhang Yulong, Xia Weizhi, Xia Fan, Liu Liyu, Wang Kuansong, Guan Yidi, Shen Taohong, Jiang Bingjian, Sun Lunquan, Cao Ayong, Wang Shouman, Li Zhi

细胞生物学

发表日期：2025

文献求助收藏

UBR5 antagonizes DNA damage to enhance the doxorubicin resistance of triple-negative breast cancer by p38 signaling.

UBR5 通过 p38 信号通路拮抗 DNA 损伤，增强三阴性乳腺癌对阿霉素的耐药性。

期刊:International Journal of Surgery

影响因子:10.1

doi:10.1097/JS9.0000000000003061

Zhang Hanghao, Shao Xinyu, Wang Xiaomin, Pang Jian, Peng Shuai, Wang Shouman, Feng Xueping, Liao Liqiu

发表日期：2025

文献求助收藏

BEBT-209, a primary CDK4 selective inhibitor, for the treatment of HR+/HER2- advanced breast cancer (BECTOP1): a phase 1, multicentre, open-label study

BEBT-209，一种选择性 CDK4 抑制剂，用于治疗 HR+/HER2- 晚期乳腺癌（BECTOP1）：一项 1 期、多中心、开放标签研究

影响因子:7.9

doi:10.1016/j.breast.2025.104527

Hu, Zhe-Yu; Jiang, Kegang; Tian, Can; Zhang, Fan; Shi, Yehui; Wang, Ying; Li, Wei; Wu, Biao; Ding, Boni; Liu, Liping; Xiao, Huawu; Yang, Xiaohong; Li, Jing; Xie, Ning; Liu, Binliang; Wang, Shouman; Ouyang, Quchang

发表日期：2025

文献求助收藏

Treatment beyond progression and rechallenge with pyrotinib in HER2-positive metastatic breast cancer and brain metastases: a multicenter real-world study

HER2阳性转移性乳腺癌和脑转移患者在疾病进展后接受吡咯替尼治疗及再次治疗：一项多中心真实世界研究

期刊:Therapeutic Advances in Medical Oncology

影响因子:4.2

doi:10.1177/17588359251387965

Peng, Jing; Chen, Qitong; Liu, Liping; Xie, Ning; Liu, Mingwen; Liu, Xuan; Qian, Liyuan; Lu, Kaili; Wu, Tao; Xie, Haiqing; Xu, Haifan; Hu, Zecheng; Ding, Sijuan; Zhou, Wei; Zhang, Chaojie; Li, Yan; Hu, Jinhui; Xie, Ruilian; He, Jing; Sun, Zhengkui; Xu, Feng; Zhang, Danhua; Long, Qian; Zhu, Jinfeng; Chen, Xi; Ouyang, Quchang; Wang, Shouman; Yi, Wenjun

发表日期：2025

文献求助收藏

Prognostic and predictive significance of neutrophil/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer

中性粒细胞/淋巴细胞比值对HER2阳性乳腺癌曲妥珠单抗治疗疗效的预后和预测意义

期刊:Scientific Reports

影响因子:3.9

doi:10.1038/s41598-025-22559-1

Cao, Jing; Pang, Jian; Li, Yan; Wang, Shouman; Xiao, Zhi; Ding, Nianhua

中性粒细胞

细胞生物学

发表日期：2025

文献求助收藏

Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial

基线中性粒细胞/淋巴细胞比值在HER2阳性转移性乳腺癌中的预后价值：CLEOPATRA试验数据的探索性分析

期刊:Breast Cancer Research

影响因子:5.6

doi:10.1186/s13058-023-01761-x

Ding, Nianhua; Pang, Jian; Liu, Xuan; He, Xiongbin; Zhou, Wei; Xie, Haiqing; Feng, Jianqi; Wang, Guo; Tang, Jie; Cao, Jing; He, Liying; He, Yingjian; Wang, Shouman; Xiao, Zhi

中性粒细胞

细胞生物学

发表日期：2024

文献求助收藏

Comparison of neoadjuvant chemotherapy response and prognosis between HR-low/HER2-negative BC and TNBC: an exploratory real-world multicentre cohort study

比较HR低/HER2阴性乳腺癌和三阴性乳腺癌新辅助化疗反应和预后：一项探索性真实世界多中心队列研究

期刊:Frontiers in Endocrinology

影响因子:4.6

doi:10.3389/fendo.2024.1347762

Peng, Jing; Hong, Yue; Chen, Qitong; Xu, Feng; Zhang, Danhua; Yao, Jia; Zou, Qiongyan; Yuan, Liqin; Li, Lun; Long, Qian; Liao, Liqiu; Liu, Mingwen; Liu, Xuan; Wang, Shouman; Yi, Wenjun

发表日期：2024

文献求助收藏